{"url_path":"/sec/obio/8-k/2026-06-23/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/1814114/0001104659-26-076845-index.html","accession_number":"0001104659-26-076845","cik":"0001814114","ticker":"OBIO","issuer_name":"Orchestra BioMed Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1814114/0001104659-26-076845-index.html","primary_entity_key":"0001814114","primary_entity_name":"Orchestra BioMed Holdings, Inc."},"word_count":656,"has_tables":true,"body_markdown":"**Item 5.07.**\n**Submission of Matters to a Vote of Security Holders.**\n\n \n\nOn June 23, 2026, Orchestra\nBioMed Holdings, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). A total\nof 59,880,715 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), were entitled to vote\nas of April 28, 2026, the record date for the Annual Meeting. There were 49,053,298 shares of Common Stock represented at the Annual Meeting,\nat which the Company’s stockholders were asked to vote on five proposals, each of which is described in more detail in the Company’s\ndefinitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 29, 2026 (the “Proxy\nStatement”). Set forth below are the matters acted upon by the Company’s stockholders, and the final voting results of each\nsuch proposal.\n\n \n\nProposal No. 1: Election of Directors\n\n \n\nVotes regarding the election of the three Class III director nominees\nwere as follows:\n\n \n\n**Director Name**\n \n**Votes For**\n \n \n**Votes Withheld**\n \n \n**Broker Non-Votes**\n \n\n**David P. Hochman**\n \n \n39,724,691\n \n \n \n97,018\n \n \n \n9,231,589\n \n\n**Darren R. Sherman**\n \n \n39,544,240\n \n \n \n277,469\n \n \n \n9,231,589\n \n\n**Eric S. Fain**\n \n \n37,810,358\n \n \n \n2,011,351\n \n \n \n9,231,589\n \n\n \n\nBased on the votes set forth above, the Company’s\nstockholders elected each of the three nominees set forth above to serve as a Class III director of the Company until the Company’s\n2029 annual meeting of stockholders and until such director’s respective successor is duly elected and qualified.\n\n \n\nProposal No. 2: Ratification of Appointment\nof Independent Registered Public Accounting Firm\n\n \n\nThe proposal to ratify the appointment of Ernst\n& Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December\n31, 2026 (the “Auditor Ratification Proposal”), received the following votes:\n\n \n\n**Votes For**\n \n \n**Votes Against**\n \n \n**Abstentions**\n \n \n**Broker Non-Votes**\n \n\n49,039,578\n \n \n \n13,692\n \n \n \n28\n \n \n \n-\n \n\n \n\nBased on the votes set forth above, the Auditor Ratification Proposal\nwas approved.\n\n \n\nProposal No. 3: Approval of the Orchestra BioMed\nHoldings, Inc. 2026 Employee Stock Purchase Plan\n\n \n\nThe proposal to approve the Orchestra BioMed Holdings,\nInc. 2026 Equity Incentive Plan (the “ESPP Proposal”) received the following votes:\n\n \n\n**Votes For**\n \n \n**Votes Against**\n \n \n**Abstentions**\n \n \n**Broker Non-Votes**\n \n\n39,639,592\n \n \n \n150,243\n \n \n \n31,874\n \n \n \n9,231,589\n \n\n \n\nBased on the votes set forth above, the ESPP Proposal was approved.\n\n \n\nProposal No. 4: Advisory, Non-Binding Vote\non the Compensation of the Company’s Named Executive Officers\n\n \n\nThe advisory (non-binding) vote on the compensation\nof the Company’s named executive officers (the “NEOs”), as set forth in the Proxy Statement, received the following\nvotes:\n\n \n\n**Votes For**\n \n \n**Votes Against**\n \n \n**Abstentions**\n \n \n**Broker Non-Votes**\n \n\n37,975,986\n \n \n \n1,778,200\n \n \n \n67,523\n \n \n \n9,231,589\n \n\n \n\n \n\n \n\n \n\nBased on the votes set forth above, the Company’s stockholders\napproved, on an advisory basis, the compensation of the NEOs.\n\n \n\nProposal No. 5: Advisory, Non-Binding Vote\non the Frequency of the Vote on the Compensation of the Company’s NEOs\n\n \n\nThe advisory (non-binding) vote on frequency of\nvotes on the compensation of the NEOs at either 1 year, 2 years or 3 years, as set forth in the Proxy Statement, received the following\nvotes:\n\n \n\n**1 Year**\n \n**2 Years**\n \n**3 Years**\n \n**Abstain**\n\n38,995,022\n \n25,675\n \n791,227\n \n9,785\n\n \n\nStockholders indicated, on an advisory basis, that they preferred that\nthere be an advisory vote on the compensation of the NEOs every “1 Year”. In light of the recommendation of the board of directors\nof the Company that future “say-on-pay” votes occur every “1 Year” and the results of the stockholder vote on\nProposal No. 5, the Company intends to submit to its stockholders a non-binding advisory vote on the compensation of the NEOs at every\nannual meeting of stockholders until the next required advisory vote on the frequency of stockholder votes on the compensation of the\nNEOs, which is expected to occur in 2032.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf\nby the undersigned hereunto duly authorized.\n\n \n\n \n**ORCHESTRA BIOMED HOLDINGS, INC.**\n\n \n \n\n \nBy:\n/s/ Andrew Taylor\n\n \nName:\nAndrew Taylor\n\n \nTitle:\nChief Financial Officer\n\n \n \n\nDate: June 23, 2026"}